Now showing items 51-53 of 53
Clinical Activity Of Loncastuximab Tesirine Plus Ibrutinib In Non‐Hodgkin Lymphoma: Updated Lotis 3 Phase 1 Results
(Wiley Periodicals, Inc., 2021-06)
Impact of initial chemotherapy regimen on outcomes for patients with double- expressor lymphoma: A multi- center analysis
(Wiley Periodicals, Inc., 2021-10)
Diffuse large B- cell lymphoma featuring overexpression of MYC and B- Cell Lymphoma 2 (double expressor lymphoma, DEL) is associated with poor outcomes. Existing evidence suggesting improved outcomes for DEL with the use ...